Arrepath was founded to discover new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state-of-the-art technologies and novel strategies. The company applies bench science, proprietary imaging and AI/ML to develop novel drugs to address global health issues. Arrepath’s advanced machine learning drug discovery platform enables the rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of the mechanism of action at the outset of the discovery process.

News Scroll

• Kevin Krause named President and CEO of ArrePath

• ArrePath Secures £1 Million Grant from PACE to Advance Novel Antibiotics Against Multidrug-Resistant Bacterial Infections

• Drug discovery startup ArrePath scores $20M and more digital health fundings

Back to homepage